Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $65 million versus the consensus estimate of $56.41 million.

GUIDANCE:

Coherus BioSciences sees FY2024 revenue of $250-265 million, versus the consensus of $259.3 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.